An update to this document was published in 2017 and is available at this link.
May 13, 2009 — An international team of device and lead management experts from North America and Europe wrote this 2009 consensus document on the management of leads in patients with cardiovascular implantable electronic devices (CIEDs). Central to this effort was a focus on transvenous lead extraction, including standards for training and for the evaluation of new tools and techniques.
May 5, 2011 — Developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA) and the Society of Thoracic Surgeons (STS), a diverse panel of experts in pacemaker and defibrillator management focused on medical procedures that might interfere with Cardiovascular Implantable Electronic Devices (CIEDs) function.
May 9, 2014 - This expert consensus statement was written by experts and developed in partnership with and endorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA); and in collaboration with and endorsed by the Heart Failure Society of America (HFSA) and the Society of Thoracic Surgeons (STS). Endorsed by the European Heart Rhythm Association (EHRA), the Asia Pacific Heart Rhythm Society (APHRS) and the Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE)-Latin American Society of Cardiac Pacing and Electrophysiology.
May 13, 2015 - The current document is developed from the foundations established by the 2008 HRS Consensus Statement as well as the 2012 International Society for Holter and Noninvasive Electrocardiography and European Heart Rhythm Association’s Expert Consensus Statement on Remote Monitoring of CIEDs. The goals of follow-up, definition of hardware, and personnel remain the same and will not be covered in this document except where evolution of remote technologies and responsibilities has occurred. The current document provides new recommendations based on data published since 2008, endorsing the need to maintain consistent follow-up, and outlining the limitations of strictly in-person methods.
The topic covered by this document includes the monitoring of CIEDs with a description of the technology, indications for use, personnel involved in monitoring and the frequency and types of monitoring events. Also covered are issues in regard to data management, regulatory environments, reimbursement and ethical considerations in respect to device inactivation.
May 14, 2010 - This document was developed in collaboration with and endorsed by the American College of Cardiology (ACC), the American Geriatrics Society (AGS), the American Academy of Hospice and Palliative Medicine (AAHPM); the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), and the Hospice and Palliative Nurses Association (HPNA). It focuses on patients nearing the end of life and addresses patients who have made a decision for CIED deactivation at other times, as well as the rights and responsibilities of clinicians (and others, such as industry-employed allied professionals) who may not wish to perform deactivation.
March 9, 2017 - Syncope has many causes and clinical presentations; the incidence depends on the population being evaluated. The purpose of this ACC/AHA/HRS guideline is to provide contemporary, accessible, and succinct guidance on the management of adult and pediatric patients with suspected syncope.
November 19, 2015 - The benefits and risks of ICD therapy for patients are directly impacted by the programming and surgical decisions made by the clinician. This expert consensus statement systemically describes four important clinical issues and addresses programming of: bradycardia mode and rate, tachycardia detection, tachycardia therapy, and intraprocedural testing of defibrillation efficacy.
December 13, 2005 — This is the first study designed to look at the relation between patient outcomes and physicians'/hospitals' volume of cardioverter-defibrillator implantation to determine whether implantation should be limited to physicians with high procedural volume.